Pfizer Inc. says it has gained US approval for a drug designed to treat menopause-related hot flashes and potentially prevent osteoporosis in postmenopausal women who have a uterus,
The United States is the first county to approve the once a day tablet called Duavee , according to Pfizer. When prescribed just for the prevention of osteoporosis in post menopause women, use of Duavee should only be considered for women at significant risk, the drug maker advised.
Common side effect of Duavee include muscle spasms, nausea, diarrhea, upset stomach, abdominal pain, throat pain, dizziness and neck pain, according to Pfizer.
One expert said women should weigh their options carefully before choosing to take the drug.